Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ana Milena Millan-Arciniegas"'
Autor:
Carlos Sanchez-Piedra, M. Victoria Hernández Miguel, Javier Manero, Rosa Roselló, Jesús Tomás Sánchez-Costa, Carlos Rodríguez-Lozano, Cristina Campos, Eduardo Cuende, Jesús Carlos Fernández-Lopez, Sagrario Bustabad, Raquel Martín Domenech, Eva Pérez-Pampín, Javier del Pino-Montes, Ana Milena Millan-Arciniegas, Federico Díaz-González, Juan Jesús Gómez-Reino
Publikováno v:
Reumatología Clínica (English Edition). 15:229-236
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e2333b0f38286e2cdb76de28c00b96eb
https://doi.org/10.1016/j.reumae.2017.08.005
https://doi.org/10.1016/j.reumae.2017.08.005
Autor:
Eduardo Cuende, M. Victoria Hernández Miguel, Raquel Martín Domenech, Rosa Roselló, Jesús T. Sánchez-Costa, Carlos Sánchez-Piedra, Javier del Pino-Montes, Jesús Carlos Fernández-Lopez, Carlos Rodríguez-Lozano, Ana Milena Millan-Arciniegas, Javier Manero, Eva Perez-Pampin, en representación del Grupo de trabajo Biobadaser Fase, Juan J. Gomez-Reino, Sagrario Bustabad, Federico Díaz-González, Cristina Campos
Publikováno v:
Reumatología Clínica. 15:229-236
Objective Describe the objectives, methods and results of the first year of the new version of the Spanish registry of adverse events involving biological therapies and synthetic drugs with an identifiable target in rheumatic diseases (BIOBADASER III
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2af93ac61953c02a7f7ee7d34b76908
https://doi.org/10.1016/j.reuma.2017.08.001
https://doi.org/10.1016/j.reuma.2017.08.001
Autor:
Carlos, Sanchez-Piedra, M Victoria, Hernández Miguel, Javier, Manero, Rosa, Roselló, Jesús Tomás, Sánchez-Costa, Carlos, Rodríguez-Lozano, Cristina, Campos, Eduardo, Cuende, Jesús Carlos, Fernández-Lopez, Sagrario, Bustabad, Raquel, Martín Domenech, Eva, Pérez-Pampín, Javier, Del Pino-Montes, Ana Milena, Millan-Arciniegas, Federico, Díaz-González, Juan Jesús, Gómez-Reino
Publikováno v:
Reumatologia clinica. 15(4)
Describe the objectives, methods and results of the first year of the new version of the Spanish registry of adverse events involving biological therapies and synthetic drugs with an identifiable target in rheumatic diseases (BIOBADASER III).Multicen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fbb4a00d090437c2a8c3c1b71e0fe880
https://pubmed.ncbi.nlm.nih.gov/28935290
https://pubmed.ncbi.nlm.nih.gov/28935290